FARTIN VIII ~ no so so so so so so

LOTHIAN HEALTH BOARD

Royal Infirmary of Edinburgh and Associated Hospitals 5001



Lauriston Place Edinburgh EH3 9YW Telephone 031-229 2477 Fax 031-228 2189

HAEMATOLOGY DEPARTMENT

Dr C.A. Ludlam Senior Chief MLSO's Mrs F. Turner Mr I. Abbott

Dr. R.R.C. Stewart, SNBTS Headquarters Medical Unit, Livingstone House, 39 Cowgate, Edinburgh.

Your Ref Our Ref CAL/AT Date 6 March 1992 Enquiries to Ext. No.

Dear Bob,

CHANGE OVER FROM Z8 TO HIGH POTENCY FACTOR VIII

I write to confirm that Haemophilia Directors for Scotland and Northern Ireland discussed at the recent meeting at Yorkhill Hospital, Glasgow, transition arrangements. We agreed that all. patients currently receiving Lille VIII should continue therapy with Semi-tartan and then Tartan VIII.

Patients currently receiving 28 should continue to do so until the stocks of this product are almost exhausted. I believe Dr. Perry estimated that this would occur in August. At that time we would change all patients over to high potency Tartan VIII. We feel this would be a simpler system to operate than gradually introducing the high potency VIII and slowly diminishing the use of Z8.

I wonder if it would be possible to retain a small stock of Z8 both for clinical and potential research use. As you know there is a small demand for Z8 as a source of fibrinogen! Might I suggest obtaining perhaps 100,000 units of Z8 that could be used up until its expiry date.

With best wishes, Yours sincerely,

GRO-C

C.A. Ludlam, Consultant Haematologist.

c.c. Mr. D. Mcintosh, General Manager, SNBTS, Ellen's Glen Road, Edinburgh. Professor J.D. Cash, SNBTS Headquarters Unit, Ellen's Glen Road, Edinburgh. All Haemophilia Centre Directors, Scotland and Northern Ireland.

PNS1